Comparison of effectiveness of oral tranexamic acid with that of the topical modified Kligman's formula in the treatment of melasma

Context: Melasma is an acquired disorder of hyperpigmentation presenting over the face. Modified Kligman's formula is used most commonly as treatment modality. Considering the various side effects of individual components of topical modified Kligman's formula, the use of oral tranexamic acid might be a better and safer alternative for the treatment of melasma. Aims: This study aims to compare the efficacy of oral tranexamic acid with that of topical modified Kligman's formula in the treatment of melasma. To assess the degree of improvement in pigmentation objectively using Melasma Area and Severity Index at baseline and after 4 weeks of treatment with oral tranexamic acid and topical modified Kligman's formula and to compare the side effects, if any, associated with both the modalities. Settings and Design: This was randomized, comparative, prospective, open-labeled study. Methods: This study was done in a tertiary care hospital from September 2018 to June 2019. Overall, 40 patients with clinical diagnosis of melasma were included in the study. Statistical Analysis Used: Paired t-test and unpaired t-test. Results: Improvement was noted in patients belonging to both the groups. After applying paired t-test, it was found that results were statistically significant in both the treatment groups. When both the groups were compared statistically using unpaired t-test, both the groups showed statistically equivalent results. Conclusions: Both oral tranexamic acid and modified Kligman's formula were equally effective in the treatment of melasma. Oral tranexamic acid is a better and safer alternative than the modified Kligman's formula to initiate the treatment in melasma.

[1]  Shuken Dashore,et al.  Tranexamic acid in melasma: Why and how? , 2017 .

[2]  T. Thng,et al.  Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis. , 2016, Journal of the American Academy of Dermatology.

[3]  Mira Choi,et al.  Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS Nd:YAG laser , 2013, The Journal of dermatological treatment.

[4]  B. N. Srinivas,et al.  A Clinical Study of Melasma and a Comparison of the Therapeutic Effect of Certain Currently Available Topical Modalities for its Treatment , 2013, Indian journal of dermatology.

[5]  A. Manosroi,et al.  Topical 5% tranexamic acid for the treatment of melasma in Asians: A double-blind randomized controlled clinical trial , 2012, Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology.

[6]  Vaneeta M. Sheth,et al.  Melasma: a comprehensive update: part I. , 2011, Journal of the American Academy of Dermatology.

[7]  S. Rathi,et al.  MELASMA: A CLINICO-EPIDEMIOLOGICAL STUDY OF 312 CASES , 2011, Indian journal of dermatology.

[8]  I. Majid MOMETASONE-BASED TRIPLE COMBINATION THERAPY IN MELASMA: IS IT REALLY SAFE? , 2010, Indian journal of dermatology.

[9]  S. Feldman,et al.  Melasma and its impact on health‐related quality of life in Hispanic women , 2007, The Journal of dermatological treatment.

[10]  Mi-Yeon Kim,et al.  Localized Intradermal Microinjection of Tranexamic Acid for Treatment of Melasma in Asian Patients: A Preliminary Clinical Trial , 2006, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[11]  K. Maeda,et al.  Topical trans-4-aminomethylcyclohexanecarboxylic acid prevents ultraviolet radiation-induced pigmentation. , 1998, Journal of photochemistry and photobiology. B, Biology.

[12]  C. Yong Treatment of melasma with oral administration of tranexamic acid , 2008 .

[13]  P. E. Grimes Melasma. Etiologic and therapeutic considerations. , 1995, Archives of dermatology.

[14]  A. Kligman,et al.  A new formula for depigmenting human skin. , 1975, Archives of dermatology.